37results about How to "The effect of solubilization is obvious" patented technology

The invention relates to the field of medicine, particularly to a medicine composition comprising butylphthalide and cosolvent, and aims to adopt a novel cosolvent to improve the water solubility of butylphthalide, develop clinically required solid, semisolid or liquid preparations of butylphthalide, and better exert the therapeutical effect of butylphthalide. The composition can be used for preparing a plurality of dosage forms such as tablets, capsules, ointment, cream, gel, transfusion, aqueous acupuncture, powder for injection, oral liquid and the like. Compared with the prior art, the medicine composition realizes better safety and improvement on the water solubility of butylphthalide.

The invention belongs to the technical field of deodorant preparation, and particularly relates to a liquid deodorant and a preparation method thereof. The liquid deodorant comprises, in weight percent, 0.5-2.5% of beta-cyclodextrin, 1-4% of malic acid, 1-4% of citric acid, 0.1-2% of salicylic acid, 0.5-4% of sodium bicarbonate, 0.5-2% of polyoxyethylene nonionic surfactants, 0.5-2% of essence and80-95% of water. The liquid deodorant eliminates odor molecules in original existing environments by a physical absorption and chemical neutralization mode, sterilization and disinfection componentsare added, microbial reproduction is effectively inhibited, regeneration of the odor molecules is fundamentally prevented, the essence is added, and experience and enjoyment of the deodorant are greatly improved.

The invention provides an indissolvable drug inclusion method, and belongs to the technical field of biological medicines. The method comprises the following steps of stirring and dissolving beta-cyclodextrin in water, and preparing a beta-cyclodextrin solution; adding an indissolvable drug into the beta-cyclodextrin solution in batches, fully stirring, adding an organic acid, and stirring and mixing again to prepare an inclusion solution; and adding an organic solvent into the inclusion solution, stirring to separate out an inclusion product, standing at low temperature, and filtering out the product to obtain the inclusion product. The preparation method comprises the following steps of conducting inclusion of the water indissolvable drug raw material and beta-cyclodextrin with entrapment capacity by using an inclusion-hydrotropy-recrystallization process flow, assisting the hydrotropy effect of organic acid, and carrying out recrystallization precipitation to prepare the inclusion drug composition. The method is especially suitable for pharmaceutical preparations which are difficult in water solubility, not resistant to high temperature and unstable in aqueous solution.

The invention discloses a preparing method for pharmaceutical composition capable of improving safety of compound ginkgo biloba injection. The pharmaceutical composition is mainly prepared from ginkgo biloba extract, dipyridamole extract, polysorbate extract and polyethylene glycol-12-hydroxyl stearate and is applied to injection. A cosolvent of polysorbate 80 which has safety hazard and can affect product quality in the compound ginkgo biloba injection is replaced by a cosolvent which is better in safety and more obvious in hydrotropy effect. The safety of the polyethylene glycol-12-hydroxyl stearate is higher than that of the polysorbate 80, the using amount of the polyethylene glycol-12-hydroxyl stearate is lower, the probability and the risk of untoward effects of medicine are reduced, and the safety of clinical medication is improved.

The invention discloses a levodopa nasal dry powder for treating Parkinson's dyskinesia and a preparation method thereof, the levodopa nasal dry powder is a mixture obtained by co-grinding or co-crushing levodopa and a carrier, or a mixture obtained by co-grinding or co-crushing levodopa, a carrier and other auxiliary components; and the carrier is hydroxypropyl beta-cyclodextrin (HP-beta-CD), alpha-cyclodextrin, methylated-beta-cyclodextrin, sodium alginate or lactose. According to the levodopa dry powder preparation disclosed by the invention, levodopa is rapidly absorbed into blood through a nose to achieve relatively high bioavailability and plasma concentration, so that dyskinesia caused by a switching effect is rapidly relieved, and the problems of instability of levodopa and the like caused by a solution preparation are solved. A subsequent animal pharmacokinetic test proves that the co-ground material can achieve the effect of being rapidly absorbed into blood, which means that the dyskinesia caused by the Parkinson's switch effect is possibly rapidly relieved.

The invention discloses a pharmaceutical composition for improving safety of a compound Herba Artemisiae Scopariae injection. The pharmaceutical composition is used for injection and is mainly prepared from Herba Artemisiae Scopariae extract, Bupleuri Herba extract, Radix Notoginseng extract and polyoxyl 15 hydroxystearate. A cosolvent which is better in safety and more obvious in dissolving assisting effect replaces polysorbate 80 which is used as a cosolvent, has potential safety hazards and affects quality of products in the compound Herba Artemisiae Scopariae injection, the safety of the polyoxyl 15 hydroxystearate is higher than that of the polysorbate 80, the use amount is lower, probability and risks of adverse reactions of drugs are reduced, and safety of clinical medication is improved.

The invention discloses a preparation method of a pharmaceutical composition for improving the safety of a compound radix codonopsis injection solution. The pharmaceutical composition is a pharmaceutical composition for injection, which is mainly prepared from radix codonopsis extract, rhizoma corydalis decumbentis extract, scandent schefflera root extract and tert-butyl peroxyacetate. According to the preparation method provided by the invention, a co-solvent, which has better safety and more obvious auxiliary dissolving effect, is used for replacing a co-solvent polysorbate 80 which has potential safety hazards on the compound radix codonopsis injection solution and influences product quality, the safety of the tert-butyl peroxyacetate is higher than that of the polysorbate 80 and the use amount of the tert-butyl peroxyacetate is lower; the probability and risks of untoward effects caused by medicines are reduced and the safety of clinical medication is improved.

The invention discloses a method for improving the safety of compound summer injection. According to the method, the pharmaceutical composition for injection is mainly prepared from the extracts of summer grass, snow lotus extract, silver orchid extract and enteric-coated acrylic resin. The method of the present invention adopts the co-solvent sodium benzoate that security is better, the solubilizing effect is more obvious to replace the co-solvent sodium benzoate that has potential safety hazard and influence product quality in compound summer non-injection, and the safety of enteric-coated acrylic resin is higher than sodium benzoate and The dosage is lower, reducing the probability and risk of adverse drug reactions, and improving the safety of clinical medication.

The invention discloses a pharmaceutical composition capable of improving the safety of a compound rhizoma polygonati injection. The pharmaceutical composition is characterized in that the pharmaceutical composition is an injection pharmaceutical composition prepared from a rhizoma polygonati extract, a bighead atractylodes rhizome extract, a platycodon root extract and glycerin polyoxyethylene ether hydroxystearate, wherein each 100ml solution contains 15 to 45g of rhizoma polygonati extract prepared from rhizoma polygonati, 10 to 10g of bighead atractylodes rhizome extract prepared from bighead atractylodes rhizome and 5 to 15g of platycodon root extract prepared from platycodon root, and the dosage ratio of the rhizoma polygonati to the bighead atractylodes rhizome to the platycodon root is 3 to 2 to 1. According to the pharmaceutical composition disclosed by the invention, a cosolvent which has better safety and more obvious solubilization effect is adopted to substitute a cosolvent polysorbate 80, which has potential safety hazards and affects the product quality, in the compound rhizoma polygonati injection, and the glycerin polyoxyethylene ether hydroxystearate has higher safety and lower dosage than those of the polysorbate 80, such that the probability and risk of adverse reactions of the pharmaceutical composition are reduced, and the safety of the clinical medication is improved.

The invention discloses a method for improving the safety of compound Luying injection. According to the method, the medicinal composition for injection is mainly prepared from the extract of Lu Ying, the extract of the hairy needles, the extract of the seeds of the iris and the hydrogenated castor oil. The method of the present invention adopts the co-solvent with better safety and more obvious solubilizing effect to replace the co-solvent carbomer that has potential safety hazards and affects product quality in the compound Luying injection, and the safety of hydrogenated castor oil is higher than that of carbomer. The dosage is lower, reducing the probability and risk of adverse drug reactions, and improving the safety of clinical medication.

The invention discloses a pharmaceutical composition for improving the safety of compound dijincao injection. The pharmaceutical composition is a pharmaceutical composition for injection mainly made of Dijincao extract, Bailiangjin extract, Jigucao extract and hydroxypropyl acrylate. In the present invention, the co-solvent with better safety and more obvious solubilizing effect is used to replace the co-solvent glycerin in the compound Dijincao injection, which has potential safety hazards and affects product quality, and the safety of hydroxypropyl acrylate is higher than that of glycerol Moreover, the dosage is lower, which reduces the probability and risk of adverse drug reactions and improves the safety of clinical medication.

The invention discloses a pharmaceutical composition capable of improving the safety of a compound smilax glabra injection. The pharmaceutical composition is characterized by being mainly prepared from a smilax glabra extract, a fructus shisandrae extract, a semen cuscutae extract and polyethylene glycol stearate, wherein each 100ml of solution contains 20-75g of smilax glabra extract of a smilax glabra material, 20-75g of the fructus shisandrae extract of a fructus shisandrae material and 10-35g of semen cuscutae extract of a semen cuscutae material, wherein the dosage ratio of smilax glabra to fructus shisandrae to semen cuscutae is 2 to 2 to 1. A cosolvent polysorbate 80 which has a potential safety hazard and affects the product quality in the compound smilax glabra injection is replaced with the cosolvent which is better in safety and more obvious in solubilizing effect; the polyethylene glycol stearate is higher than the polysorbate 80 in safety and lower than the polysorbate 80 in dosage; the probability and risk of an adverse effect of the medicine are reduced; and the clinical medication safety is improved.

The invention discloses a pharmaceutical composition capable of improving safety of a compound manglietia injection. The pharmaceutical composition for injection is characterized by being mainly prepared from a manglietia extract, an extract of black nightshade herb, a banana extract and polyethylene glycol dodecahydroxyl stearate, wherein each 100ml of the solution (the pharmaceutical composition) consists of the manglietia extract of 10-20g of a manglietia medicinal material, the black nightshade herb extract of 10-20g of a black nightshade herb medicinal material and the banana extract of 1-2g of a banana medicinal material, and the dosage ratio of the manglietia medicinal material to the black nightshade herb medicinal material to the banana medicinal material is 10 to 10 to 1. According to the pharmaceutical composition disclosed by the invention, a cosolvent, namely polysorbate 80, which has safety hidden dangers and has influence on product quality in the compound manglietia injection is replaced by a cosolvent which is better in safety and is more remarkable in dissolve-assisting effect with a lower dosage, so that the probability and risks of adverse reactions of the medicine (the pharmaceutical composition) are reduced, and the safety of clinical administration is improved.

The invention discloses a pharmaceutical composition capable of improving the safety of a compound andrographis injection. The pharmaceutical composition is a pharmaceutical composition for injection, prepared from andrographis extract, coptis chinensis extract, radix isatidis extract and hexafluorobutyl methacrylate. According to the invention, a cosolvent, polysorbate 80, which has potential safety hazards and influences the product quality in the compound andrographis injection is replaced with a cosolvent with better safety and more obvious solubilizing effect, the hexafluorobutyl methacrylate is higher in safety than the polysorbate 80 and is low in usage amount, the probability and risk of causing adverse reactions of the drug can be reduced, and the clinical medication safety is improved.

The invention discloses a pharmaceutical composition for improving the safety of compound Dinggongteng injection, the pharmaceutical composition is mainly composed of Dinggongteng extract, rhubarb extract, hair holly extract and hexafluorobutyl methacrylate for injection pharmaceutical composition. The present invention adopts the co-solvent with better safety and more obvious solubilizing effect to replace the co-solvent polysorbate 80, which has potential safety hazards and affects product quality in the compound Dinggongteng injection, and the safety of hexafluorobutyl methacrylate is higher than that of polysorbate The ester 80 is high and the dosage is lower, which reduces the probability and risk of adverse drug reactions and improves the safety of clinical medication.

The invention discloses a pharmaceutical composition for improving the safety of compound angelica injection. The pharmaceutical composition is a pharmaceutical composition for injection mainly made of angelica extract, astragalus extract, notoginseng extract and methyl methacrylate. The present invention adopts the co-solvent with better safety and more obvious solubilizing effect to replace the co-solvent phenoxyethanol which has potential safety hazards and affects product quality in the compound angelica injection, and the safety of methyl methacrylate is higher than that of phenoxyethanol. The dosage is lower, reducing the probability and risk of adverse drug reactions, and improving the safety of clinical medication.